Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Relyvrio

Sodium Phenylbutyrate; Taurursodiol

DiscontinuedRLDNDA 216660 Amylyx
Approved
Sep 29, 2022
Strengths
1
Listed patents
5

What does the FDA Orange Book show for Relyvrio?

Relyvrio contains Sodium Phenylbutyrate; Taurursodiol and is the new drug FDA Orange Book record for NDA 216660. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 216660

New drug application identity from the Orange Book snapshot.

Application holder
Amylyx Pharmaceuticals Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
5

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
2

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0013GM/PACKET; 1GM/PACKETFOR SUSPENSIONORALDiscontinuedNone posted
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Amylyx Pharmaceuticals Inc

The Orange Book identifies this organization as the applicant responsible for NDA 216660.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as on the Discontinued Drug Product List

A discontinued-list entry does not, by itself, show why marketing stopped or whether FDA determined the product was withdrawn for safety or effectiveness.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

5 listed patent expirations and 2 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jul 27, 2040. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 216660 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

For Suspension · Oral

Sodium Phenylbutyrate; Taurursodiol

1 application
Product rows
1
Active applications
0
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-216660

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 216660
RLDDiscontinued
Strength
3GM/PACKET; 1GM/PACKET
Dosage form
FOR SUSPENSION
Route
ORAL
Marketing status
Discontinued

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    3 yr 11 mo ago

  2. Today

  3. Exclusivity ends · NCE

    New chemical entity exclusivity (5 years)

    in 1 yr 2 mo

  4. Exclusivity ends · ODE-411

    Orphan-drug exclusivity (7 years)

    in 3 yr 3 mo

  5. Patent 10251896 expires

    Listed method-of-use patent (U-3460) expiration.

    in 7 yr 6 mo

  6. Patent 10857162 expires

    Listed method-of-use patent (U-3460) expiration.

    in 7 yr 6 mo

  7. Patent 11071742 expires

    Listed drug product patent expiration.

    in 7 yr 6 mo

  8. Patent 9872865 expires

    Listed method-of-use patent (U-3460) expiration.

    in 7 yr 6 mo

  9. Patent 11583542 expires

    Listed drug product patent expiration.

    in 14 yr 3 mo

Patent & exclusivity timeline

Protection horizon
20262028203020322034203620382040TodayExclusivity NCE: 2027-09-29Exclusivity NCEExclusivity ODE-411: 2029-09-29Exclusivity ODE-411Patent 10251896: 2033-12-24Patent 10251896Patent 10857162: 2033-12-24Patent 10857162Patent 11071742: 2033-12-24Patent 11071742Patent 9872865: 2033-12-24Patent 9872865Patent 11583542: 2040-07-27Patent 11583542
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

SODIUM PHENYLBUTYRATE; TAURURSODIOL

Strength

3GM/PACKET; 1GM/PACKET

Dosage form

FOR SUSPENSION

Route

ORAL

TE code

Not listed

Application

NDA 216660

Product number

001

Marketing status

Discontinued

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Marketing exclusivity

Hatch-Waxman
  • NCENew chemical entity exclusivity (5 years)

    in 1 yr 2 mo

  • ODE-411Orphan-drug exclusivity (7 years)

    in 3 yr 3 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10251896in 7 yr 6 mo
U-3460
10857162in 7 yr 6 mo
U-3460
11071742in 7 yr 6 mo
Product
9872865in 7 yr 6 mo
U-3460
11583542in 14 yr 3 mo
Product

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Sodium Phenylbutyrate; Taurursodiol family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Relyvrio: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 216660 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo